Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Valeritas Holdings Inc. (VLRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/09/2019 |
GN
| Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting |
| 11/15/2019 |
GN
| Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage |
| 10/29/2019 |
GN
| Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019) |
| 10/21/2019 |
GN
| GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study |
| 10/10/2019 |
GN
| Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting |
| 10/02/2019 |
GN
| Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock |
| 09/26/2019 |
GN
| Valeritas Announces Participation on “The Cutting Edge of Cannabinoid Science” Panel at the CBD Expo EAST Conference |
| 09/24/2019 |
GN
| Valeritas Presents Positive h-Patch™ CBD Study Data at CannMed Conference |
| 09/19/2019 |
GN
| Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference |
| 09/12/2019 |
GN
| Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit |
| 08/29/2019 |
GN
| Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 08/15/2019 |
GN
| Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas' V-Go® Meets Primary A1c Endpoint |
| 07/30/2019 |
GN
| Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study |
| 07/22/2019 |
GN
| Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019 |
| 07/08/2019 |
GN
| Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population |
| 06/27/2019 |
GN
| Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device |
| 06/24/2019 |
GN
| Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold |
| 05/31/2019 |
GN
| Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 05/28/2019 |
GN
| American Diabetes Association Includes “Disposable Patch-Like Device,” such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019 |
| 05/22/2019 |
GN
| Valeritas' V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population |
| 05/17/2019 |
GN
| Valeritas Announces Reverse Stock Split |
| 05/13/2019 |
GN
| Valeritas Exhibits at Taking Control of Your Diabetes Conferences |
| 05/02/2019 |
GN
| Valeritas Expects First Quarter Revenue of $6.4 million |
| 04/29/2019 |
GN
| Valeritas to Present at Upcoming Investor Conferences |
| 04/26/2019 |
GN
| Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14% |
| 04/22/2019 |
GN
| Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019 |
| 04/17/2019 |
GN
| Market Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group — Emerging Consolidated Expectations, Analyst Ratings |
| 04/08/2019 |
GN
| Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment |
| 04/01/2019 |
GN
| Valeritas partners with the American Association of Diabetes Educators (AADE) |
| 03/28/2019 |
GN
| Valeritas Announces V-Go® Distribution Agreement in Israel |
| 03/05/2019 |
GN
| Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results |
| 02/28/2019 |
GN
| Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 02/21/2019 |
GN
| Switching to Valeritas' V-Go® Wearable Insulin Delivery Device from Insulin Pen Devices for Basal-Bolus Therapy Improved Glycemic Control with Less Insulin |
| 02/19/2019 |
GN
| Valeritas to Present at Upcoming Investor Conferences |
|
|
|